Abstract

A method to alter anesthetic drug specificity for anesthetic-sensitive channels and receptors.  It is anticipated that new compounds can be developed from this method which would target specific channels and receptors.  A UC Davis researcher has identified several novel compounds with predicted receptor specificities that may yield clinically beneficial anesthetic, analgesic, and sedative effects.

Full Description

A researcher at the University of California, Davis has discovered a way to modify the receptor specificity of anesthetic drugs.  This invention may create new compounds, or modify drugs, that have desirable anesthetic, analgesic, and sedative properties.

Applications

This invention has application to both clinical anesthetic drug development and to the development of research pharmaceuticals where specific receptor agonists/antagonists are often required.

Features/Benefits

There is currently no known alternative for achieving N-methyl-D-aspartate (NMDA) versus gamma-aminobutyric acid (GABA) receptor specificity for a family of compounds.  This invention may modify any anesthetic or candidate anesthetic receptor-acitivity profile at low-affinity sites by small structural changes.

PATENT STATUS

• Patent Pending

INVENTORS

• Brosnan, Robert J.

Other Information

Contact

Randi L. Jenkins/ rljenkins@ucdavis.edu / tel: 530-754-7650. Please reference Tech ID #19237.

Request Additional Information